Premium
Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer
Author(s) -
Allen Aaron M.,
Elshaikh Mohamed,
Worden Francis P.,
Bradford Carol R.,
Teknos Theodoros N.,
Chepeha Douglas B.,
Tsien Christina,
Dawson Laura A.,
Urba Susan,
Wolf Gregory T.,
Normolle Daniel,
Eisbruch Avraham
Publication year - 2007
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.20495
Subject(s) - regimen , medicine , head and neck cancer , cisplatin , head and neck squamous cell carcinoma , enteral administration , fluorouracil , surgery , toxicity , chemotherapy , radiation therapy , oncology , parenteral nutrition
Background. Our aim was to evaluate the acceleration of a hyperfractionated, concurrent chemoradiation regimen (HxCRT) for advanced head and neck squamous cell carcinoma (HNSCC). Methods. Patients with unresectable HNSCC were treated based on a previously published HxCRT regimen: 1.25 Gy twice daily to 70 Gy concurrent with cisplatin 12 mg/m 2 /day and5‐fluorouracil 600 mg/m 2 /day for 5 days, weeks 1, 5. This regimen was accelerated in this series by shortening the treatment from 7 to 6 weeks by omitting the planned mid‐treatment 1‐week break. Results. Forty‐six patients with T3‐4/N3 disease were treated. The main acute toxicity was pharyngeal. Median weight change during therapy in patients with and without enteral feeding tubes was −3.8% and −7.9%, respectively ( p = .08). Fifteen percent had late grade III pharyngeal toxicity. Local/regional and distant failure rates were 28% and 17%, respectively; 52% are alive without evidence of disease. Conclusions. In nonresectable HNSCC, acceleration of the HxCRT regimen is feasible, requiring enteral feeding tubes during therapy in most patients. © 2006 Wiley Periodicals, Inc. Head Neck, 2007